medigraphic.com
ISSN 0185-3325 (Impreso)
Órgano Oficial del Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz

2024, Número 4

<< Anterior

Salud Mental 2024; 47 (4)


Physical Comorbidity and Healthcare Utilization in People with Schizophrenia: a systematic review

Salvador M, Porras-Segovia A, Lopez-Fernandez O, Baca-García E

Idioma: Español
Referencias bibliográficas: 92
Paginas: 189-204
Archivo PDF: 307.23 Kb.


RESUMEN

Introducción. La esquizofrenia puede provocar una discapacidad significativa y tener un impacto notable en el funcionamiento social y ocupacional. Este trastorno tiende a disminuir la esperanza de vida debido a una variedad de factores, incluidos malos hábitos de salud, obstáculos para acceder a la atención médica y el estigma a las enfermedades mentales. Objetivo. La presente revisión sistemática pretende examinar la comorbilidad física de estos pacientes y su uso de los servicios de salud. Método. El protocolo registrado en la base de datos PROSPERO (CRD42020139972) sigue las directrices Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). A través de PubMed/MEDLINE, EMBASE, Scopus, Web of Science, PsycINFO, Cochrane Library y ProQuest Health Research Premium Collection se identificaron 317 artículos y se seleccionaron 57. Resultados. Las personas que padecen esquizofrenia se enfrentan a una tasa de mortalidad que supera al menos el doble de la población general, y son susceptibles a enfermedades cardiovasculares, respiratorias, diabetes mellitus, oncológicas e infecciones crónicas, que pueden disminuir su esperanza de vida. Las complicaciones durante la hospitalización y las estancias prolongadas dificultan su atención sanitaria. Discusión y conclusión. Los sistemas de salud requieren mejoras para brindar una atención adecuada a los pacientes con esquizofrenia y ayudar a incrementar su esperanza de vida. Además, estos pacientes se benefician de adoptar estilos de vida saludables, tratar la dependencia de sustancias y adaptar el tratamiento antipsicótico. Parece crucial ejecutar estrategias de intervención y capacitar a los profesionales clínicos para poder detectar y manejar las comorbilidades físicas asociadas a este trastorno mental.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Attar, R., Berg Johansen, M., Valentin, J. B., Aagaard, J., & Jensen, S. E. (2017).Treatment following myocardial infarction in patients with schizophrenia. PloSOne, 12(12), e0189289. https://doi.org/10.1371/journal.pone.0189289

  2. Bailey, E. A., Wirtalla, C., Sharoky, C. E., & Kelz, R. R. (2018). Disparities inoperative outcomes in patients with comorbid mental illness. Surgery, 163(4),667-671. https://doi.org/10.1016/j.surg.2017.09.029

  3. Bauer-Staeb, C., Jörgensen, L., Lewis, G., Dalman, C., Osborn, D. P. J., & Hayes, J. F.(2017). Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in peoplewith severe mental illness: a total population study of Sweden. The Lancet -Psychiatry, 4(9), 685-693. https://doi.org/10.1016/S2215-0366(17)30253-5

  4. Bernardo, M., Rico-Villademoros, F., García-Rizo, C., Rojo, R., & Gómez-Huelgas,R. (2021). Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients:A Systematic Review of Population-Based Studies. Advances in Therapy, 38(5),2491-2512. https://doi.org/10.1007/s12325-021-01689-8

  5. Bitter, I., Czobor, P., Borsi, A., Fehér, L., Nagy, B. Z., Bacskai, M., Rakonczai,P., Hegyi, R., Németh, T., Varga, P., Gimesi-Országh, J., Fadgyas-Freyler,P., Sermon, J., … Takács, P. (2017). Mortality and the relationship ofsomatic comorbidities to mortality in schizophrenia. A nationwide matchedcohortstudy. European psychiatry, 45, 97-103. https://doi.org/10.1016/j.eurpsy.2017.05.022

  6. Bodén, R., Molin, E., Jernberg, T., Kieler, H., Lindahl, B., & Sundström, J. (2015).Higher mortality after myocardial infarction in patients with severe mentalillness: a nationwide cohort study. Journal of Internal Medicine, 277(6), 727-736. https://doi.org/10.1111/joim.12329

  7. Bouza, C., López-Cuadrado, T., & Amate, J. M. (2010a). Hospital admissions dueto physical disease in people with schizophrenia: a national population-basedstudy. General Hospital Psychiatry, 32(2), 156-163. https://doi.org/10.1016/j.genhosppsych.2009.11.014

  8. Bouza, C., López-Cuadrado, T., & Amate, J. M. (2010b). Physical disease inschizophrenia: a population-based analysis in Spain. BMC Public Health, 10,745. https://doi.org/10.1186/1471-2458-10-745

  9. Bradford, D. W., Goulet, J., Hunt, M., Cunningham, N. C., & Hoff, R. (2016). ACohort Study of Mortality in Individuals With and Without SchizophreniaAfter Diagnosis of Lung Cancer. The Journal of Clinical Psychiatry, 77(12),e1626-e1630. https://doi.org/10.4088/JCP.15m10281

  10. Brink, M., Green, A., Bojesen, A. B., Lamberti, J. S., Conwell, Y., & Andersen, K.(2017). Physical Health, Medication, and Healthcare Utilization among 70-Year-Old People with Schizophrenia: A Nationwide Danish Register Study. AmericanJournal of Geriatric Psychiatry, 25(5), 500-509. doi: 10.1016/j.jagp.2016.12.015

  11. Brink, M., Green, A., Bojesen, A. B., Lamberti, J. S., Conwell, Y., & Andersen,K. (2019). Excess medical comorbidity and mortality across the lifespan inschizophrenia: A nationwide Danish register study. Schizophrenia Research,206, 347-354. https://doi.org/10.1016/j.schres.2018.10.020

  12. Carney, C. P., Jones, L., & Woolson, R. F. (2006). Medical comorbidity in womenand men with schizophrenia: a population-based controlled study. Journal ofGeneral Internal Medicine, 21(11), 1133-1137. https://doi.org/10.1111/j.1525-1497.2006.00563.x

  13. Chen, P. H., Tsai, S. Y., Pan, C. H., Chang, H. M., Chen, Y. L., Su, S. S., Chen. C.C., & Kuo, C. J. (2021). Age Effect on Incidence, Physical, and PsychiatricComorbidity for Sudden Cardiac Death in Schizophrenia: Effet de l’âge surl’incidence, la comorbidité physique et psychiatrique de la mort cardiaque subitedans la schizophrénie. Canadian Journal of Psychiatry / Revue Canadienne dePsychiatrie, 66(4), 367-375. https://doi.org/10.1177/0706743720948429

  14. Cloutier, M., Aigbogun, M. S., Guerin, A., Nitulescu, R., Ramanakumar, A. V.,Kamat, S. A., DeLucia, M., Duffy, R., Legacy, S. N., Henderson, C., Francois,C., & Wu, E. (2016). The Economic Burden of Schizophrenia in the UnitedStates in 2013. The Journal of Clinical Psychiatry, 77(6), 764-771. https://doi.org/10.4088/JCP.15m10278

  15. Contreras-Shannon, V., Heart, D. L., Paredes, R. M., Navaira, E., Catano, G., Maffi,S. K., & Walss-Bass, C. (2013). Clozapine-induced mitochondria alterationsand inflammation in brain and insulin-responsive cells. PloS One, 8(3), e59012.https://doi.org/10.1371/journal.pone.0059012

  16. Copeland, L. A., Mortensen, E. M., Zeber, J. E., Pugh, M. J., Restrepo, M. I., &Dalack, G. W. (2007). Pulmonary disease among inpatient decedents: Impactof schizophrenia. Progress in Neuro-psychopharmacology & BiologicalPsychiatry, 31(3), 720-726. https://doi.org/10.1016/j.pnpbp.2007.01.008

  17. Copeland, L. A., Zeber, J. E., Rosenheck, R. A., & Miller, A. L. (2006). Unforeseeninpatient mortality among veterans with schizophrenia. Medical Care, 44(2),110-116. https://doi.org/10.1097/01.mlr.0000196973.99080.fb

  18. Correll, C. U., Ng-Mak, D. S., Stafkey-Mailey, D., Farrelly, E., Rajagopalan, K., &Loebel, A. (2017). Cardiometabolic comorbidities, readmission, and costs inschizophrenia and bipolar disorder: a real-world analysis. Annals of GeneralPsychiatry, 16, 9. https://doi.org/10.1186/s12991-017-0133-7

  19. Correll, C. U., Solmi, M., Croatto, G., Schneider, L. K., Rohani-Montez, S. C.,Fairley, L., Smith, N., Bitter, I., Gorwood, P., Taipale, H., & Tiihonen, J. (2022).Mortality in people with schizophrenia: a systematic review and meta-analysisof relative risk and aggravating or attenuating factors. World Psychiatry, 21(2),248-271. https://doi.org/10.1002/wps.20994

  20. D’Avanzo, B., La Vecchia, C., & Negri, E. (2003). Mortality in long-stay patientsfrom psychiatric hospitals in Italy--results from the Qualyop Project. SocialPsychiatry and Psychiatric Epidemiology, 38(7), 385-389. https://doi.org/10.1007/s00127-003-0646-z

  21. Dalton, S. O., Suppli, N. P., Ewertz, M., Kroman, N., Grassi, L., & Johansen, C. (2018).Impact of schizophrenia and related disorders on mortality from breast cancer:A population-based cohort study in Denmark, 1995-2011. Breast (Edinburgh,Scotland), 40, 170-176. https://doi.org/10.1016/j.breast.2018.06.002

  22. Daumit, G. L., Pronovost, P. J., Anthony, C. B., Guallar, E., Steinwachs, D. M., &Ford, D. E. (2006). Adverse events during medical and surgical hospitalizationsfor persons with schizophrenia. Archives of General Psychiatry, 63(3), 267-272.https://doi.org/10.1001/archpsyc.63.3.267

  23. DE Hert, M., Correll, C. U., Bobes, J., Cetkovich-Bakmas, M., Cohen, D., Asai, I.,Detraux, J., Gautam, S., Möller, H. J., Ndetei, D. M., Newcomer, J. W., Uwakwe,R., & Leucht, S. (2011). Physical illness in patients with severe mental disorders.I. Prevalence, impact of medications and disparities in health care. WorldPsychiatry, 10(1), 52-77. https://doi.org/10.1002/j.2051-5545.2011.tb00014.x

  24. Douzenis, A., Seretis, D., Nika, S., Nikolaidou, P., Papadopoulou, A., Rizos, E. N.,Christodoulou, C., Tsopelas, C., Mitchell, D., & Lykouras, L. (2012). Factorsaffecting hospital stay in psychiatric patients: the role of active comorbidity.BMC Health Services Research, 12, 166. https://doi.org/10.1186/1472-6963-12-166

  25. Foley, D. L., Mackinnon, A., Morgan, V. A., Watts, G. F., Castle, D. J., Waterreus,A., & Galletly, C. A. (2016). Common familial risk factors for schizophreniaand diabetes mellitus. The Australian and New Zealand Journal of Psychiatry,50(5), 488-494. https://doi.org/10.1177/0004867415595715

  26. Fond, G., Salas, S., Pauly, V., Baumstarck, K., Bernard, C., Orleans, V., Llorca, P. M.,Lancon, C., Auquier, P., & Boyer, L. (2019). End-of-life care among patientswith schizophrenia and cancer: a population-based cohort study from the Frenchnational hospital database. The Lancet - Public Health, 4(11), e583-e591.https://doi.org/10.1016/S2468-2667(19)30187-2

  27. Gabilondo, A., Alonso-Moran, E., Nuño-Solinis, R., Orueta, J. F., & Iruin, A.(2017). Comorbidities with chronic physical conditions and gender profilesof illness in schizophrenia. Results from PREST, a new health dataset.Journal of Psychosomatic Research, 93, 102-109. https://doi.org/10.1016/j.jpsychores.2016.12.011

  28. Goldman, L. S. (1999). Medical illness in patients with schizophrenia. The Journal ofClinical Psychiatry, 60(Suppl 21), 10-15.

  29. Goueslard, K., Petit, J. M., Cottenet, J., Chauvet-Gelinier, J. C., Jollant, F., &Quantin, C. (2018). Increased Risk of Rehospitalization for Acute DiabetesComplications and Suicide Attempts in Patients with Type 1 Diabetes andComorbid Schizophrenia. Diabetes Care, 41(11), 2316-2321. https://doi.org/10.2337/dc18-0657

  30. Guadalajara, H., Lopez-Fernandez, O, León Arellano, M., Domínguez-Prieto, V.,Caramés, C., & Garcia-Olmo, D. (2022). The Role of Shared Decision-Makingin Personalised Medicine: Opening the Debate. Pharmaceuticals, 15(2), 215.https://doi.org/10.3390/ph15020215

  31. Gur, S., Weizman, S., Stubbs, B., Matalon, A., Meyerovitch, J., Hermesh, H., &Krivoy, A. (2018). Mortality, morbidity and medical resources utilization ofpatients with schizophrenia: A case-control community-based study. PsychiatryResearch, 260, 177-181. https://doi.org/10.1016/j.psychres.2017.11.042

  32. Gyllensten, A. L., Ovesson, M. N., Hedlund, L., Ambrus, L., & Tornberg, Å.(2020). To increase physical activity in sedentary patients with affective - orschizophrenia spectrum disorders - a clinical study of adjuvant physical therapyin mental health. Nordic Journal of Psychiatry, 74(1), 73-82. https://doi.org/10.1080/08039488.2019.1669706

  33. Hauck, T. S., Liu, N., Wijeysundera, H. C., & Kurdyak, P. (2020). Mortalityand Revascularization among Myocardial Infarction Patients withSchizophrenia: A Population-Based Cohort Study. Canadian Journal ofPsychiatry / Revue Canadienne de Psychiatrie, 65(7), 454-462. https://doi.org/10.1177/0706743720904845

  34. Hayes, J. F., Marston, L., Walters, K., King, M. B., & Osborn, D. P. J. (2017).Mortality gap for people with bipolar disorder and schizophrenia: UK-basedcohort study 2000-2014. The British Journal of Psychiatry: The Journal ofMental Science, 211(3), 175-181. https://doi.org/10.1192/bjp.bp.117.202606

  35. Heiberg, I. H., Jacobsen, B. K., Balteskard, L., Bramness, J. G., Naess, Ø., Ystrom,E., Reichborn-Kjennerud, T., Hultman, C. M., Nesvåg, R., & Høye, A. (2019).Undiagnosed cardiovascular disease prior to cardiovascular death in individualswith severe mental illness. Acta Psychiatrica Scandinavica, 139(6), 558-571.https://doi.org/10.1111/acps.13017

  36. Hjorthøj, C., Stürup, A. E., McGrath, J. J., & Nordentoft, M. (2017). Years ofpotential life lost and life expectancy in schizophrenia: a systematic review andmeta-analysis. The Lancet - Psychiatry, 4(4), 295-301. https://doi.org/10.1016/S2215-0366(17)30078-0

  37. Hou, P. Y., Hung, G. C., Jhong, J. R., Tsai, S. Y., Chen, C. C., & Kuo, C. J. (2015).Risk factors for sudden cardiac death among patients with schizophrenia.Schizophrenia Research, 168(1-2), 395-401. https://doi.org/10.1016/j.schres.2015.07.015

  38. Huang, C. J., Hsieh, H. M., Tu, H. P., Jiang, H. J., Wang, P. W., & Lin, C. H.(2018). Schizophrenia in type 2 diabetes mellitus: Prevalence and clinicalcharacteristics. European Psychiatry, 54, 102-108. https://doi.org/10.1016/j.eurpsy.2018.08.002

  39. Hughes, J. R. (1993). Possible effects of smoke-free inpatient units on psychiatricdiagnosis and treatment. The Journal of Clinical Psychiatry, 54(3), 109-114.

  40. Ishikawa, H., Yasunaga, H., Matsui, H., Fushimi, K., & Kawakami, N. (2016).Differences in cancer stage, treatment and in-hospital mortality between patientswith and without schizophrenia: retrospective matched-pair cohort study. TheBritish Journal of Psychiatry: The Journal of Mental Science, 208(3), 239-244.https://doi.org/10.1192/bjp.bp.114.156265

  41. Jeste, D. V., Gladsjo, J. A., Lindamer, L. A., & Lacro, J. P. (1996). Medicalcomorbidity in schizophrenia. Schizophrenia Bulletin, 22(3), 413-430. https://doi.org/10.1093/schbul/22.3.413

  42. Jørgensen, M., Mainz, J., Lange, P., & Paaske Johnsen, S. (2018). Quality of careand clinical outcomes of chronic obstructive pulmonary disease in patients withschizophrenia. A Danish nationwide study. International Journal for Quality inHealth Care, 30(5), 351-357. https://doi.org/10.1093/intqhc/mzy014

  43. Kisely, S., Forsyth, S., & Lawrence, D. (2016). Why do psychiatric patients havehigher cancer mortality rates when cancer incidence is the same or lower? TheAustralian and New Zealand Journal of Psychiatry, 50(3), 254-263. https://doi.org/10.1177/0004867415577979

  44. Korpela, H., Miettunen, J., Rautio, N., Isohanni, M., Järvelin, M. R., Jääskeläinen,E., Auvinen, J., Keinänen-Kiukaanniemi, S., Nordström, T., & Seppälä, J.(2020). Early environmental factors and somatic comorbidity in schizophreniaand nonschizophrenic psychoses: A 50-year follow-up of the Northern FinlandBirth Cohort 1966. European Psychiatry, 63(1), e24. https://doi.org/10.1192/j.eurpsy.2020.25

  45. Koskinen, J., Löhönen, J., Koponen, H., Isohanni, M., & Miettunen, J. (2009).Prevalence of alcohol use disorders in schizophrenia--a systematic reviewand meta-analysis. Acta Psychiatrica Scandinavica, 120(2), 85-96. https://doi.org/10.1111/j.1600-0447.2009.01385.x

  46. Kowalski, K., & Misiak, B. (2023). Schizophrenia and the COVID-19 pandemic:A narrative review from the biomedical perspective. Revista de Psiquiatría ySalud Mental, S1888-9891(23), 00015-0. Advance online publication. https://doi.org/10.1016/j.rpsm.2023.04.002

  47. Kugathasan, P., Laursen, T. M., Grøntved, S., Jensen, S. E., Aagaard, J., & Nielsen,R. E. (2018). Increased long-term mortality after myocardial infarction inpatients with schizophrenia. Schizophrenia Research, 199, 103-108. https://doi.org/10.1016/j.schres.2018.03.015

  48. Kugathasan, P., Stubbs, B., Aagaard, J., Jensen, S. E., Munk Laursen, T., & Nielsen,R. E. (2019). Increased mortality from somatic multimorbidity in patientswith schizophrenia: a Danish nationwide cohort study. Acta PsychiatricaScandinavica, 140(4), 340-348. https://doi.org/10.1111/acps.13076

  49. Kurdyak, P., Vigod, S., Duchen, R., Jacob, B., Stukel, T., & Kiran, T. (2017). Diabetesquality of care and outcomes: Comparison of individuals with and withoutschizophrenia. General Hospital Psychiatry, 46, 7-13. https://doi.org/10.1016/j.genhosppsych.2017.02.001

  50. Lambert, T. J., Velakoulis, D., & Pantelis, C. (2003). Medical comorbidity inschizophrenia. The Medical Journal of Australia, 178(S9), S67-S70. https://doi.org/10.5694/j.1326-5377.2003.tb05311.x

  51. Lasser, K., Boyd, J. W., Woolhandler, S., Himmelstein, D. U., McCormick, D.,& Bor, D. H. (2000). Smoking and mental illness: A population-basedprevalence study. JAMA, 284(20), 2606-2610. https://doi.org/10.1001/jama.284.20.2606

  52. Laursen, T. M., Munk-Olsen, T., & Gasse, C. (2011). Chronic somatic comorbidityand excess mortality due to natural causes in persons with schizophrenia orbipolar affective disorder. PloS One, 6(9), e24597. https://doi.org/10.1371/journal.pone.0024597

  53. Laursen, T. M., Nordentoft, M., & Mortensen, P. B. (2014). Excess early mortality inschizophrenia. Annual Review of Clinical Psychology, 10, 425-448. https://doi.org/10.1146/annurev-clinpsy-032813-153657

  54. Laursen, T. M., Plana-Ripoll, O., Andersen, P. K., McGrath, J. J., Toender, A., Nordentoft,M., Canudas-Romo, V., & Erlangsen, A. (2019). Cause-specific life years lost amongpersons diagnosed with schizophrenia: Is it getting better or worse? SchizophreniaResearch, 206, 284-290. https://doi.org/10.1016/j.schres.2018.11.003

  55. Lee, E. E., Liu, J., Tu, X., Palmer, B. W., Eyler, L. T., & Jeste, D. V. (2018). A wideninglongevity gap between people with schizophrenia and general population: Aliterature review and call for action. Schizophrenia Research, 196, 9-13. https://doi.org/10.1016/j.schres.2017.09.005

  56. Leucht, S., Burkard, T., Henderson, J., Maj, M., & Sartorius, N. (2007). Physical illnessand schizophrenia: a review of the literature. Acta Psychiatrica Scandinavica,116(5), 317-333. https://doi.org/10.1111/j.1600-0447.2007.01095.x

  57. Lin, G. M., Chen, Y. J., Kuo, D. J., Jaiteh, L. E., Wu, Y. C., Lo, T. S., & Li, Y. H.(2013). Cancer incidence in patients with schizophrenia or bipolar disorder:anationwide population-based study in Taiwan, 1997-2009. SchizophreniaBulletin, 39(2), 407-416. https://doi.org/10.1093/schbul/sbr162

  58. Lu, M. L. R., De Venecia, T. A., Goyal, A., Rodriguez Ziccardi, M., Kanjanahattakij,N., Shah, M. K., Davila, C. D, & Figueredo, V. M. (2017). Psychiatricconditions as predictors of rehospitalization among African American patientshospitalized with heart failure. Clinical Cardiology, 40(11), 1020-1025. https://doi.org/10.1002/clc.22760

  59. Martens, P. J., Chochinov, H. M., Prior, H. J., Fransoo, R., Burland, E., & Need toKnow Team. (2009). Are cervical cancer screening rates different for womenwith schizophrenia? A Manitoba population-based study. SchizophreniaResearch, 113(1), 101-106. https://doi.org/10.1016/j.schres.2009.04.015

  60. Martinez-Nicolas, I., Basaraba, C., Delgado-Gomez, D., Lopez-Fernandez, O., Baca-Garcia, E., Wainberg, M. L. (2023b). The Electronic Mental Wellness Tool asa Self-Administered Brief Screening Instrument for Mental Disorders in theGeneral Spanish Population during the Post-COVID-19 Era. InternationalJournal of Environmental Research and Public Health, 20(4), 3204. https://doi.org/10.3390/ijerph20043204

  61. Martínez-Nicolás, I., Molina-Pizarro, C.A., Franco, A.R., Arenas Castañeda, P. E.,Maya, C., Barahona, I., Martínez-Alés, G., Aroca Bisquert, F., Delgado-Gomez,D., Dervic, K., Lopez-Fernandez, O., Baca-García, E., & Barrigón, M. L.(2023a). What seems to explain suicidality in Yucatan Mexican young adults?Findings from an app-based mental health screening test using the SMARTSCREENprotocol. Current Psychology, 42(35), 30767-30779). https://doi.org/10.1007/s12144-022-03686-8

  62. McGinty, E. E., Baller, J., Azrin, S. T., Juliano-Bult, D., & Daumit, G. L. (2015).Quality of medical care for persons with serious mental illness: A comprehensivereview. Schizophrenia Research, 165(2-3), 227-235. https://doi.org/10.1016/j.schres.2015.04.010

  63. McGrath, J., Saha, S., Chant, D., & Welham, J. (2008). Schizophrenia: a conciseoverview of incidence, prevalence, and mortality. Epidemiologic Reviews, 30,67-76. https://doi.org/10.1093/epirev/mxn001

  64. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & PRISMA Group. (2009).Preferred reporting items for systematic reviews and meta-analyses: thePRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097

  65. Nielsen, P. R., Laursen, T. M., & Agerbo, E. (2016). Comorbidity of schizophrenia andinfection: a population-based cohort study. Social Psychiatry and PsychiatricEpidemiology, 51(12), 1581-1589. https://doi.org/10.1007/s00127-016-1297-1

  66. Nordentoft, M., Plana-Ripoll, O., & Laursen, T. M. (2021). Cancer and schizophrenia.Current Opinion in Psychiatry, 34(3), 260-265. https://doi.org/10.1097/YCO.0000000000000697

  67. Oud, M. J., & Meyboom-de Jong, B. (2009). Somatic diseases in patients withschizophrenia in general practice: their prevalence and health care. BMC FamilyPractice, 10, 32. https://doi.org/10.1186/1471-2296-10-32

  68. Oud, M. J., Schuling, J., Groenier, K. H., Verhaak, P. F., Slooff, C. J., Dekker, J. H., &Meyboom-de Jong, B. (2010). Care provided by general practitioners to patientswith psychotic disorders: a cohort study. BMC Family Practice, 11, 92. https://doi.org/10.1186/1471-2296-11-92

  69. Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C.D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., Chou, R., Glanville,J., Grimshaw, J. M., Hróbjartsson, A., Lalu, M. M., Li, T., Loder, E. W., Mayo-Wilson, E., McDonald, S., ... Moher, D. (2021). The PRISMA 2020 statement:an updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71

  70. Pankiewicz-Dulacz, M., Stenager, E., Chen, M., & Stenager, E. N. (2019). Riskfactors of major infections in schizophrenia. A nationwide Danish register study.Journal of Psychosomatic Research, 121, 60-67. https://doi.org/10.1016/j.jpsychores.2019.04.003

  71. Partti, K., Vasankari, T., Kanervisto, M., Perälä, J., Saarni, S. I., Jousilahti, P.,Lönnqvist, J., & Suvisaari, J. (2015). Lung function and respiratory diseasesin people with psychosis: population-based study. The British Journal ofPsychiatry, 207(1), 37-45. https://doi.org/10.1192/bjp.bp.113.141937

  72. Poirier, M. F., Canceil, O., Baylé, F., Millet, B., Bourdel, M. C., Moatti, C., Olié,J. P., & Attar Lévy, D. (2002). Prevalence of smoking in psychiatric patients.Progress in Neuro-Psychopharmacology & Biological Psychiatry, 26(3), 529-537. https://doi.org/10.1016/s0278-5846(01)00304-9

  73. Polcwiartek, C., Kragholm, K., Rohde, C., Hashemi, N., Vang, T., & Nielsen, J.(2017). Diabetic ketoacidosis and diabetes associated with antipsychoticexposure among a previously diabetes-naive population with schizophrenia: anationwide nested case-control study. Diabetologia, 60(9), 1678-1690. https://doi.org/10.1007/s00125-017-4320-5

  74. Porras-Segovia, A., Krivoy, A., Horowitz, M., Thomas, G., Bolstridge, M., Ion, D.,& Shergill, S. S. (2017). Rapid-onset clozapine-induced loss of glycaemiccontrol: case report. BJPsych Open, 3(3), 138-140. https://doi.org/10.1192/bjpo.bp.117.004481

  75. Räsänen, S., Hakko, H., Viilo, K., Meyer-Rochow, V. B., & Moring, J. (2003).Excess mortality among long-stay psychiatric patients in Northern Finland.Social Psychiatry and Psychiatric Epidemiology, 38(6), 297-304. https://doi.org/10.1007/s00127-003-0635-2

  76. Razzano, L. A., Cook, J. A., Yost, C., Jonikas, J. A., Swarbrick, M. A., Carter, T. M.,& Santos, A. (2015). Factors associated with co-occurring medical conditionsamong adults with serious mental disorders. Schizophrenia Research, 161(2-3),458-464. https://doi.org/10.1016/j.schres.2014.11.021

  77. Rodrigues, M., Wiener, J. C., Stranges, S., Ryan, B. L., & Anderson, K. K. (2021).The risk of physical multimorbidity in people with psychotic disorders: Asystematic review and meta-analysis. Journal of Psychosomatic Research, 140,110315. https://doi.org/10.1016/j.jpsychores.2020.110315

  78. Salokangas, R. K. (2007). Medical problems in schizophrenia patients living in thecommunity (alternative facilities). Current Opinion in Psychiatry, 20(4), 402-405. https://doi.org/10.1097/YCO.0b013e328122d99b

  79. Schoepf, D., Potluri, R., Uppal, H., Natalwala, A., Narendran, P., & Heun, R. (2012).Type-2 diabetes mellitus in schizophrenia: increased prevalence and majorrisk factor of excess mortality in a naturalistic 7-year follow-up. EuropeanPsychiatry, 27(1), 33-42. https://doi.org/10.1016/j.eurpsy.2011.02.009

  80. Schoepf, D., Uppal, H., Potluri, R., & Heun, R. (2014). Physical comorbidity andits relevance on mortality in schizophrenia: a naturalistic 12-year follow-upin general hospital admissions. European Archives of Psychiatry and ClinicalNeuroscience, 264(1), 3-28. https://doi.org/10.1007/s00406-013-0436-x

  81. Schulman-Marcus, J., Goyal, P., Swaminathan, R. V., Feldman, D. N., Wong, S. C.,Singh, H. S., Minutello, R. M., Bergman, G., & Kim, L. K. (2016). Comparisonof Trends in Incidence, Revascularization, and In-Hospital Mortality in STElevationMyocardial Infarction in Patients with Versus Without Severe MentalIllness. The American Journal of Cardiology, 117(9), 1405-1410. https://doi.org/10.1016/j.amjcard.2016.02.006

  82. Shen, H. N., Lu, C. L., & Yang, H. H. (2011). Increased risks of acute organdysfunction and mortality in intensive care unit patients with schizophrenia: anationwide population-based study. Psychosomatic Medicine, 73(7), 620-626.https://doi.org/10.1097/PSY.0b013e3182280016

  83. 83 Sohn, M., Moga, D. C., & Talbert, J. (2015). Mental disorder comorbidity and inhospitalmortality among patients with acute myocardial infarction. GeriatricMental Health Care, 3(1), 7-11. https://doi.org/10.1016/j.gmhc.2015.04.002

  84. Soontornniyomkij, V., Lee, E. E., Jin, H., Martin, A. S., Daly, R. E., Liu, J., Tu, X.M., Eyler, L. T., & Jeste, D. V. (2019). Clinical Correlates of Insulin Resistancein Chronic Schizophrenia: Relationship to Negative Symptoms. Frontiers inPsychiatry, 10, 251. https://doi.org/10.3389/fpsyt.2019.00251

  85. Sørensen, H. J., Nielsen, P. R., Benros, M. E., Pedersen, C. B., & Mortensen,P. B. (2015). Somatic diseases and conditions before the first diagnosis ofschizophrenia: a nationwide population-based cohort study in more than900 000 individuals. Schizophrenia Bulletin, 41(2), 513-521. https://doi.org/10.1093/schbul/sbu110

  86. Spilsbury, K., Rosenwax, L., Brameld, K., Kelly, B., & Arendts, G. (2018). Morbidityburden and community-based palliative care are associated with rates of hospitaluse by people with schizophrenia in the last year of life: A population-basedmatched cohort study. PloS One, 13(11), e0208220. https://doi.org/10.1371/journal.pone.0208220

  87. Stahl, S. M., Mignon, L., & Meyer, J. M. (2009). Which comes first: atypicalantipsychotic treatment or cardiometabolic risk? Acta Psychiatrica Scandinavica,119(3), 171-179. https://doi.org/10.1111/j.1600-0447.2008.01334.x

  88. Tanskanen, A., Tiihonen, J., & Taipale, H. (2018). Mortality in schizophrenia: 30-year nationwide follow-up study. Acta Psychiatrica Scandinavica, 138(6), 492-499. https://doi.org/10.1111/acps.12913

  89. Tokuda, Y., Obara, H., Nakazato, N., & Stein, G. H. (2008). Acute care hospitalmortality of schizophrenic patients. Journal of Hospital Medicine, 3(2), 110-116. https://doi.org/10.1002/jhm.256

  90. Torous, J., Firth, J., Mueller, N., Onnela, J. P., & Baker, J. T. (2017). Methodologyand Reporting of Mobile Heath and Smartphone Application Studies forSchizophrenia. Harvard Review of Psychiatry, 25(3), 146-154. https://doi.org/10.1097/HRP.0000000000000133

  91. Urrútia, G., & Bonfill, X. (2010). Declaración PRISMA: una propuesta para mejorarla publicación de revisiones sistemáticas y metaanálisis [PRISMA declaration: aproposal to improve the publication of systematic reviews and meta-analyses].Medicina Clínica, 135(11), 507-511. https://doi.org/10.1016/j.medcli.2010.01.015

  92. Vancampfort, D., Firth, J., Schuch, F. B., Rosenbaum, S., Mugisha, J., Hallgren,M., Probst, M., Ward, P. B., Gaughran, F., De Hert, M., Carvalho, A. F., &Stubbs, B. (2017). Sedentary behavior and physical activity levels in peoplewith schizophrenia, bipolar disorder and major depressive disorder: a globalsystematic review and meta-analysis. World Psychiatry, 16(3), 308-315. https://doi.org/10.1002/wps.20458




2020     |     www.medigraphic.com